The AI-focused drug developer received cash from new and existing investors that could include Lundbeck and Upsher-Smith Laboratories.

BenevolentAI, a UK-based, healthcare-focused artificial intelligence technology developer backed by pharmaceutical companies Lundbeck and Upsher-Smith Laboratories, raised $115m today from unnamed new and existing investors at a $2bn pre-money valuation. The only participant named in the round, which the company said increased its overall funding to more than $200m, was fund manager Woodford Investment Management.…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.